ADCT
ADC Therapeutics SA
NYSE: ADCT · HEALTHCARE · BIOTECHNOLOGY
$3.78
+0.27% today
Updated 2026-04-29
Market cap
$480.78M
P/E ratio
—
P/S ratio
5.91x
EPS (TTM)
$-1.12
Dividend yield
—
52W range
$1 – $5
Volume
0.9M
ADC Therapeutics SA (ADCT) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+45.7%
Last 4 quarters
Revenue YoY growth
+36.4%
Most recent quarter
EPS YoY growth
+84.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-8.6%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-15.4%
2026-03-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-12 | $-0.04 | +86.6% | $4.88 | $4.13 | -15.4% |
| 2025-11-10 | $-0.19 | +47.2% | $4.04 | $3.97 | -1.7% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.30 | $-0.04 | +86.6% | $23.06M | +36.4% |
| 2025-09-30 | $-0.36 | $-0.19 | +47.2% | $16.43M | -11.0% |
| 2025-06-30 | $-0.39 | $-0.25 | +35.9% | $18.84M | +8.2% |
| 2025-03-31 | $-0.41 | $-0.36 | +13.1% | $23.03M | +27.6% |
| 2024-12-31 | $-0.43 | $-0.25 | +41.9% | $16.91M | +0.7% |
| 2024-09-30 | $-0.38 | $-0.42 | -10.5% | $18.46M | +27.4% |
| 2024-06-30 | $-0.46 | $-0.38 | +17.4% | $17.41M | -9.7% |
| 2024-03-31 | $-0.56 | $-0.56 | +0.0% | $18.05M | -4.9% |
| 2023-12-31 | $-0.50 | $-1.03 | -106.0% | $16.79M | — |
| 2023-09-30 | $-0.63 | $-0.58 | +7.9% | $14.49M | — |
| 2023-06-30 | $-0.46 | $-0.58 | -26.1% | $19.28M | — |
| 2023-03-31 | $-0.67 | $-0.74 | -10.4% | $18.99M | — |
| 2022-12-31 | $-0.29 | $-0.30 | -3.4% | — | — |
Frequently asked questions
Has ADC Therapeutics SA beaten earnings estimates?
ADC Therapeutics SA has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +45.7% over the last 4 quarters.
How does ADCT stock react to earnings?
ADCT stock has moved an average of -8.6% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is ADC Therapeutics SA's revenue growth rate?
ADC Therapeutics SA reported year-over-year revenue growth of +36.4% in its most recent quarter, with EPS growing +84.0% year-over-year.